应对耐多药结核病方面取得的进展
但这些病例中有多少是耐多药结核病？
问：你什么时候开始介入耐多药结核病问题的？
因此，出现各种耐多药结核病管理不善的情况。
As a result all kinds of poor management of MDR-TB are happening.
问：哈萨克斯坦与耐多药结核病作斗争的核心内容是什么？
Q: What's the most important part of Kazakhstan's fight against drug-resistant TB?
耐多药结核病是所有国家面临的一个挑战，这是由于该病治疗起来存有难度并且费用昂贵。
MDR-TB is a threat to all countries as it is difficult and expensive to treat.
耐多药结核病是所有国家面临的一个挑战，这是由于该病治疗起来存有难度并且费用昂贵。
MDR-TB is a threat to all countries as it is difficult and expensive to treat.
应用推荐